Sunlight vs. Embody vs. Gala: The New Low-Price Tier Compared
A new wave of GLP-1 providers has driven starting prices below $200/month. Here's how the three most competitive options actually compare.
The New Price Floor
Through most of 2024 and early 2025, compounded GLP-1 treatment averaged $250–400/month from telehealth providers. That floor has dropped significantly. Three providers now offer entry-level semaglutide treatment under $200/month — and the differences between them matter more than the pricing alone.
The Three-Way Comparison
Sunlight — $159/mo Semaglutide (First Month)
Sunlight entered the market in June 2026 as our current Editor's Pick with aggressive introductory pricing: $159 for semaglutide in the first month, $179 ongoing. Tirzepatide starts at $239 first month, $259 ongoing. The program includes online consultation, medication, and shipping.
Strengths: Lowest tirzepatide entry price among the three. Clean onboarding process. Both semaglutide and tirzepatide available. Weaknesses: Newest entrant, so less track record. Long-term pricing ($179–259/mo ongoing) is mid-range rather than budget.
Embody — $149/mo First Month
Embody offers the lowest absolute entry price at $149 for the first month of injectable semaglutide, with refills at $299/month. This is injectable semaglutide only — Embody does not offer oral tirzepatide or any tirzepatide formulations through their standard program.
Strengths: Lowest first-month price on the market. Established platform with operational track record. Straightforward injectable-only model. Weaknesses: The jump from $149 to $299 on refills is the steepest price increase among the three. No tirzepatide option.
Gala — $179/mo Flat
Gala differentiates with flat-rate pricing: $179/month with no introductory teasers and no price increases as doses escalate. What you pay in month one is what you pay in month twelve. This is significant because most providers charge more at higher doses.
Strengths: True flat pricing eliminates dose-escalation surprises. Predictable budgeting. No hidden fees. Weaknesses: Higher initial price than Sunlight or Embody. The flat-rate model may include margin for higher doses built into the baseline price.
The 12-Month Cost Comparison
First-month pricing can be misleading. Here's what a full year actually costs at standard dosing:
| Provider | Month 1 | Months 2–12 | 12-Month Total |
|---|---|---|---|
| Sunlight (sema) | $159 | $179 × 11 | $2,128 |
| Gala (sema) | $179 | $179 × 11 | $2,148 |
| Embody (sema) | $149 | $299 × 11 | $3,438 |
Over 12 months, the lowest first-month price (Embody at $149) becomes the most expensive option due to the $299 refill rate. Sunlight and Gala end up within $20 of each other annually, with Sunlight slightly cheaper and Gala offering more predictability.
Our Verdict
For long-term value on semaglutide, Sunlight edges out the competition with the lowest 12-month cost and both semaglutide and tirzepatide availability. Gala is the better choice for patients who value pricing predictability and hate surprises. Embody is best suited for patients who want to test GLP-1 treatment at the lowest possible entry cost before committing to a long-term provider.
If you need tirzepatide specifically, Sunlight is the only option among these three.
See All Provider Pricing
Compare monthly and annual costs across every verified GLP-1 provider.
View Full Comparison →